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Cardiac output (CO) measurement has long been considered essential to the assessment and guidance of therapeutic decisions
in critically ill patients and for patients undergoing certain high-risk surgeries. Despite controversies, complications and inherent
errors in measurement, pulmonary artery catheter (PAC) continuous and intermittent bolus techniques of CO measurement
continue to be the gold standard. Newer techniques provide less invasive alternatives; however, currently available monitors are
unable to provide central circulation pressures or true mixed venous saturations. Esophageal Doppler and pulse contour monitors
can predict ﬂuid responsiveness and have been shown to decrease postoperative morbidity. Many minimally invasive techniques
continue to suﬀer from decreased accuracy and reliability under periods of hemodynamic instability, and so few have reached the
level of interchangeability with the PAC.
1. CardiacOutputAssessed byInvasiveand
MinimallyInvasiveTechniques
Cardiacoutput(CO)measurementhaslongbeenconsidered
essential to the assessment and guidance of therapeutic deci-
sions in critically ill patients, by providing an indirect indica-
tion of systemic oxygen delivery and global tissue perfusion.
Perioperatively, CO monitoring has become virtually routine
for certain high-risk patients and in major surgeries, where
large ﬂuid shifts are expected.
2. History
The technique was ﬁrst described in 1870 by Adolf Fick [1],
who computed an animal’s CO by utilizing oxygen concen-
trations in arterial and venous blood samples, where CO
is equal to oxygen consumption (VO2), divided by arterial
oxygen content (CaO2) minus mixed venous oxygen content
(CvO2)[ 2, 3]:
CO =
VO2
(CaO2 −CvO2) ×10
. (1)
Pulmonary artery catheterization was ﬁrst performed exper-
imentally in dogs by Grehant and Quinquaud in 1886, but
the technique would not become available to humans for an-
other ﬁfty years [4].
Indicator-dilution techniques later developed. In 1897,
Stewart described experiments pioneering the indicator-
dilutionprinciple,whenheinjectedsodiumchlorideintothe
central circulation of animals and measured its subsequent
concentration in the femoral artery [5]. Hamilton modiﬁed
this principle to account for the varying concentrations of
diluted injectate over time in human circulation, developing
a time concentration curve to reﬂect this phenomenon [2].
CO was shown to equal the quantity of indicator dye (indo-
cyanine green) injected, divided by the area under the dil-
ution curve measured downstream, today known as the Ste-
wart-Hamilton equation [5]:
Flow =
C0V0 
c(t)dt
,( 2 )
where C0 denotes initial injectate concentration and V0 rep-
resents initial injectate volume. The denominator represents
the concentrationof diluted injectate over time, thus the area
under the dilution curve.
Based on the same concept as indicator-dilution meth-
ods, Fegler introduced thermodilution (TD) in 1954 by inj-
ecting a cold solution as an indicator and measuring changes2 Anesthesiology Research and Practice
in blood temperature detected distally [6]. In 1970, Swan
et al. developed what they termed a “ﬂow-directed balloon-
tipped” multiple lumen catheter, the pulmonary artery cath-
eter (PAC) [7]. The introduction of the PAC enabled phy-
sicians to measure CO by TD both at the bedside and intra-
operatively. Forty years later, this method is still considered
the clinical gold standard for CO measurement, secondary to
its extensive utilization in a variety of clinical settings.
3. Intermittent Bolus Pulmonary
Artery Thermodilution
The TD technique is founded on the law of conservation of
energy [9]. A known amount of cold solution is injected
through the proximal port of a PAC into the right atrium,
and this solution is detected distally by a thermistor several
centimeters from the end of PAC. The change in blood tem-
perature detected causes a change in the thermistor resis-
tance, allowing for the calculation of the area under the TD
curve. CO is determined from a modiﬁed Stewart-Hamilton
equation [10, 11]:
CO =
VI∗(TB − TI) ∗K1 ∗K2 
ΔTB(t)dt
,( 3 )
w h e r eV Ii si n j e c t a t ev o l u m e ,T Bi sb l o o dt e m p e r a t u r e ,T I
is injectate temperature, K1 is a density factor: (speciﬁc
heat (injectate) × speciﬁc gravity (injectate))/(speciﬁc heat
(blood) × speciﬁc gravity (blood)), and K2i sac o m p u t a t i o n
constant accounting for heat exchange in transit, injection
rate, and catheter dead space. The denominator, change of
blood temperature as a function of time, reﬂects the area
under the TD curve (Figure 1)[ 6].
4. Reliabilityof Thermodilution
DespitebeingconsideredthegoldstandardtechniqueforCO
measurement, the reproducibility of TD technique has been
heavily scrutinized and, to our knowledge, no data on the
subject has been published in the last 20 years. Studies
continue to quote statistical signiﬁcance as demonstrated by
Stetz et al. in 1982 [12], where the accuracy of TD was com-
pared to that of Fick and dye-dilution methods. The con-
clusion was that all three methods are “of equal merit.” The
intrinsic reproducibility of TD measurements was also an-
alyzed, with the conclusion being that there must be a min-
imal diﬀerence of 12–15% between three serial CO deter-
minations, to suggest clinical signiﬁcance [12]. The inherent
error of TD measurement, has subsequently been quoted in
this manner.
4.1. Sources of Error. Accurate CO estimation can only be
made if several assumptions are true. The amount of cold
injectate must remain constant between the injection and
detection sites. There must be complete mixing of blood and
injectate and no ﬂuctuations in baseline blood temperature
during measurement [9]. Sources of error may be considered
to be technical or intrinsic to certain physiologic states.
Technical errors can be due to loss of indicator before,
during, or after injection, variability of temperature and vol-
ume of injectate, and thermistor malfunction. Although TD
was ﬁrst performed with 10mL of iced 5% dextrose water,
most studies over time have demonstrated no diﬀerence in
accuracy when iced or room-temperature injectate was used
[2, 10, 13]. When using an iced indicator, rewarming of
injectate prior to administration and heat transfer during
transit can both result in an overestimation of CO. When the
volume of indicator injected is less than the assumed am-
ount, an overestimation of CO can occur. Recommended
volumes are 10mL for adults and 0.15mL/kg for children
[6]. A clot over the catheter tip or contact with a vessel wall
due to a wedged catheter can insulate the thermistor and
result in spurious measurements. An injection time of 4 sec-
onds or less with steady pressure has been recommended to
prevent a delayed upstroke of the TD curve. Coiling of the
catheter may change the distance from the injection site to
the tip and also introduce error [6].
Both physiologic and pathologic states can lead to inac-
curate CO measurements. Fluctuations in baseline pulmo-
nary artery temperature occur with cardiac and respiratory
oscillations. Rewarming in the initial minutes after cardiac
bypass results in a transient decrease in core body tempera-
tureasheatdistributestotheperiphery.Measurementstaken
at this time can signiﬁcantly underestimate the true CO [14].
Simultaneous rapid intravenous infusions have also been
shown to alter computed CO [2].
It should be emphasized that TD with a PAC measures
right ventricular outﬂow and not systemic CO. Intracardiac
shunts can, therefore, lead to inaccurate measurements. In
patients with left-to-right shunts, early recirculation of in-
jection results in a subsequent distortion of the downward
slope of the TD curve [15]. In the presence of right-to-left
shunts, a portion of the indicator will bypass the thermistor,
resulting in an overestimation of CO. Both pulmonary and
tricuspid valve insuﬃciencies can likewise lead to unreliable
CO determinations. The recirculation of indicator across
incompetent valves can overestimate or underestimate CO,
depending on the severity of the regurgitation and the
underlying systemic CO [2].
Spontaneous and mechanical ventilation both alter right
ventricular output throughout the respiratory cycle more so
than left ventricular outﬂow. Studies evaluating the eﬀects
of the mechanical ventilatory cycle on TD measurements re-
veal inspiratory decreases in right ventricular ejection fra-
ction and subsequent increases in right ventricular end sys-
tolic volumes [16]. A fall in left-sided CO, however, is large-
ly prevented by the increase in right ventricular end diastolic
volume. These ﬁndings explain the greater ventilatory mod-
ulation of right ventricular volumes. In the past, measure-
mentstakenattheendofexpirationwerethoughttoproduce
the greatest reproducibility. On the contrary, it is argued that
more reliable estimations of mean TD CO should be taken
from three to four serial CO measurements at diﬀerent phas-
es of the cycle [6]. Some authors recommend at least eight
measurements taken randomly at diﬀerent times during the
ventilatory cycle [16].Anesthesiology Research and Practice 3
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Figure 1: Thermodilution cardiac output curves. Used with permission from [8].
5. ContinuousPulmonary
Artery Thermodilution
Applying the same principles of TD, newer technologies ap-
plied to PACs allow continuous CO measurements. By util-
izing an electric ﬁlament incorporated into the right ventric-
ular portion of the PAC, blood ﬂowing through the right
heart is heated intermittently, approximately 15 to 25cm
proximal to the PAC tip. The resulting thermal signal is mea-
sured by a thermistor at the catheter tip. CO measurements
by continuous TD have been shown to generally correlate
well with intermittent bolus measurement [2]. These cath-
eters provide a continuous trend of CO, decrease operator
workload, and possibly reduce infection risk associated with
bolus technique. However, since the values displayed are up-
dated every 30 to 60 seconds, what is reﬂected is the average
value for CO measured over the previous 5–15 minutes [9].
Leibowitz and Oropello [17] studied average in vivo time
delays associated with sudden changes in CO of critically ill
patients. The mean in vivo response times were reported to
be 9.3, 10.5, and 11.8 minutes for a 50, 75, and 90% re-
sponse, respectively [17]. Due to these inherent time delays,
many clinicians argue these continuous monitors should be
considered a “continual” rather than continuous real-time
monitor [15]. These catheters may therefore be less optimal
in detecting and measuring abrupt CO changes, but could be
a more accurate representation of global CO.
5.1. Controversies Regarding Use. In the early 1980’s, studies
demonstrated improved outcomes with both perioperative
and intensive care utilization of pulmonary artery catheter-
ization [17]. However, in 1987, Gore et al. [18] published a
study showing that mortality from myocardial infarction ac-
tually increased with PAC use. Although this investigation
was merely a case-control, chart review study without retro-
spective risk adjustment, the article led to an editorial calling
for a “moratorium” on PAC use [19].
Studies using the PAC to optimize cardiac index, mixed
venous oxygen saturation (Sv02), and oxygen delivery have
failed to show any reduction in morbidity and mortality
of critically ill patients. In the large multicenter, SUPPORT
study, a propensity score using multivariable logistic regres-
sion, looked at the association between right heart catheter-
ization and speciﬁc outcomes. Investigators revealed an in-
crease in 30-day mortality in patients with PACs [20]. The
National Heart, Lung, and Blood Institute (NHLBI) and
Food and Drug Administration (FDA) have published a con-
sensus statement advocating for RCTs with the PAC in pa-
tients with congestive heart failure (CHF), acute respiratory
distresssyndrome(ARDS),sepsis,andsepticshock,aswellas
low-risk coronary artery bypass graft surgery (CABG) [21].
5.2.EvidencefromRandomizedControlledTrials. In2003,the
Canadian Critical Care Clinical Trials Group reported the
largest RCT to date, comparing goal-directed therapy using
a PAC versus standard care with a central venous catheter
(CVC) [22]. There were no diﬀerences in hospital mortality,
median length of stay (LOS), or one-year survival rates,
despite an increased use of inotropic agents, vasodilators,
antihypertensives, and erythrocyte and colloid transfusions
in the PAC group. PAC-related adverse events occurred
in 1.5% of patients versus 0.7% related to central venous
catheter use alone [22].
In 2005, the PAC-Man study, a RCT done in United
Kingdom ICUs, also failed to show evidence of beneﬁt or
harm with PAC management [23]. The LOS in the ICU and
hospital and days of organ support required were similar
in patients managed with and without a PAC. There was
a 10% (46 in 486) incidence of direct complications due
to PAC use, the most frequent being hematoma formation,
arterial puncture, and arrhythmias. This study, similar to
Sandham et al. [22], refuted the claim of increased mortality
associated with catheter use. Other studies utilizing a PAC in
patients with severe sepsis, septic shock, and/or ARDS failed
to show a change in mortality rate [24–26]. In 2006, low-
risk patients undergoing oﬀ-pump, beating-heart surgery
showed no diﬀerence in operative mortality or outcome
variables between patients with or without PACs [27].4 Anesthesiology Research and Practice
The ESCAPE trial, funded by the NHLBI, evaluated the
eﬀectiveness of PACs guiding therapy in patients with severe
CHF [28]. The use of the PAC had no eﬀect on the primary
endpoint of days alive out of hospital; however, a trend for
“greater functional improvement after therapy guided by the
PAC” was reported [28]. A concurrent PAC registry was
established for hospitalized heart failure patients with a PAC
who were not randomized to the trial. The study has been
criticizedforexcluding patientswithahigherdiseaseseverity
andmortalityrisk[29].Inaddition,notreatmentprotocolor
proven therapy was directed towards PAC use [30]. Due to a
lack of goal-directed therapy, both groups of patients likely
received similar interventions.
A RCT conducted by the NHLBI Acute Respiratory Dis-
tress Syndrome (ARDS) Clinical Trials Network in 2006
compared treatment of acute lung injury in patients man-
aged with PACs versus CVCs [25]. There were no statistical
diﬀerences in mortality in the ﬁrst 60 days before discharge
home, ventilator free days, or LOS in ICU. The PAC group
received more red blood cell transfusions and had approx-
imately twice as many catheter-related complications, most
commonly arrhythmias.
Why is it that, despite such detailed hemodynamic in-
formation, PACs fail to improve patient outcomes? One sug-
gestion is that the lack of goal-directed therapy tailored
towards PAC use has prevented us from altering morbidity
and mortality. Pulmonary artery catheterization should be
seen as a diagnostic tool and not mistaken to be therapeutic
[31].
6.MinimallyandNoninvasiveTechniques
Although TD may be considered the gold standard for CO
measurement,its use is limited, mainly because of the associ-
ated risks of pulmonary artery catheterization (arrhythmias,
valvular lesions, infection, pulmonary emboli, pulmonary
infarction, and pulmonary artery rupture). Additional costs
arealsosigniﬁcant.TheidealtechniqueforCOmeasurement
is minimally or noninvasive, is continuous, does not require
calibration,andisaccurate,reproducible,andreliableduring
variousphysiologicstates[32].Amultitudeofnewtechnolo-
gies for CO measurement have been developed and are now
available for clinical use (Table 1).
6.1. Methods of Comparison. Studies of reliability, accuracy,
and precision of newer methods of CO measurement gener-
ally involve a comparison with more established techniques,
such as TD. In the past, correlation and regression analysis
was used, however, Bland-Altman analysis has become the
preferred method of statistical analysis for determining level
of agreement. The diﬀerence between comparative measure-
ment is plotted (the bias) against the mean values of each
pair of readings. The standard deviation (SD) of each bias
measurement is calculated and 95% conﬁdence limits drawn
(μ ± 2SD). The latter is the limits of agreement, upon which
a determination of precision is based [33].
L. A. H. Critchley and J. A. J. H. Critchley [33]p e r -
formed a meta-analysis and found wide variations in the
presentation of statistical data for comparison studies. They
advocated that studies present the mean CO (μ), the bias,
the limits of agreement (95% C.I.), and the percentage error
(±2SD/μ) and concluded that acceptance of a new technique
shouldrelyonlimitsofagreementofupto ±30%.Theypoint
out that the Bland-Altman method does not compensate for
the magnitude of the measurements and the size of the error
andsuggestthatpercentageerrorbe calculatedforeachsetof
data as opposed to calculating it one time from the averaged
data.
7. Pulse Power Analysis
Pulse power analysis is based on the theory that ﬂuctuations
of blood pressure about the mean are directly related to the
stroke volume (SV) ejected into the arterial system [34]. Ac-
curacy of measurement is complicated by several factors.
(i) Nonlinear compliance of the arterial wall. Decreased
aortic compliance occurs at higher than at lower
blood pressures (BPs).
(ii) Wave reﬂection, since pulse pressure detected in a
peripheral artery is a composite of the pressure wave
from ejection from the heart and the reﬂected
pressure wave from the distal arterial tree. Changes in
systemic vascular resistance (SVR) aﬀect the reﬂected
wave augmentation of the arterial pressure. The size
of the reﬂected waves is also found to vary with the
sampling site proximity to the central circulation and
patient age.
(iii) Damping of the transducer system.
(iv) Aortic systolic outﬂow. Filling is pulsatile; however,
outﬂow tends to be continuous [34].
The LiDCO method of pulse power analysis utilizes a pro-
prietary autocorrelation algorithm (PulseCO (LiDCO, Cam-
bridge, UK)) which addresses the factors mentioned above.
The assumption made is that, following calibration and cor-
rection for compliance, there is conservation of mass/power
and so a linear relationship exists between net power and
net ﬂow. Autocorrelation allows for the determination of
the beat period as well as the net power change across the
whole beat from the stroke volume. As a result, the eﬀect of
reﬂected waves is negated. Since the method is time based,
the eﬀects of arterial damping are minimized. Apart from
extreme conditions, the pulse power tends to remain the
same regardless of the degree of damping [34].
The LiDCO plus (Cambridge, UK) system is coupled
to a lithium dilution system, a technique ﬁrst described by
Linton et al. [35] in 1993. Either central or peripheral venous
access may be used in addition to a peripheral arterial line,
to which a disposable lithium sensitive sensor is attached.
The sensor membrane contains an ionophore which is
selectively permeable to lithium [36]. The membrane voltage
is related to the plasma lithium concentration using the
Nernst equation. The voltage is ampliﬁed and digitalized for
analysis. Sodium supplies the baseline voltage in the absence
of lithium.Anesthesiology Research and Practice 5
Table 1: Comparison of minimally invasive cardiac output monitoring techniques (CI: cardiac index, HR: heart rate, and ECG: electro-
cardiogram).
Technique Advantages Additional
variables Invasiveness Limitations
LiDCO plus Continuous CO measurement SV Arterial line Requires good ﬁdelity of arterial waveform
Useful in goal-directed therapy SVV Peripheral or
central venous line Calibration aﬀected by neuromuscular blockers
Contraindicated in lithium therapy
Requires transpulmonary lithium dilution calibration
PiCCO plus Continuous CO measurement GEDV Arterial line Requires good ﬁdelity of arterial waveform
EVLV Requires transpulmonary thermodilution calibration
SVV
PPV
FloTrac/Vigileo Continuous CO measurement SVV Arterial line Requires good ﬁdelity of arterial waveform
No calibration required
NICO Ease of use Shunt Endotracheal
intubation Aﬀected by changes in dead space or V/Q matching
Ventilatory
variables
Valid only with
PaCO2 > 30mmHg
Bioimpedance Noninvasive Cutaneous
electrodes Aﬀe c t e db ye l e c t r i c a ln o i s e ,m o v e m e n t
Continuous CO measurement Electrode contact aﬀected by temperature and humidity
Requires hemodynamic stability
Not useful in dysrhythmias
Bioreactance Noninvasive Continuous CO
measurement
Cutaneous
electrodes
ECOM SV Endotracheal
intubation Coronary blood ﬂow not recorded
CI Electrocautery produces interference
SVR No fully validated human studies
HR, ECG
Ultrasound
dilution
Measures ﬂow in ECMO and
hemodialysis circuits Arterial line Fluid overload with saline injection in sensitive patients
Central venous
catheterization Errors from indicator loss in inadequate lung perfusion
Errors in the presence of septal defects
TEE Used to evaluate cardiac SV Esophageal probe Mainly used perioperatively
anatomy and function, preload,
and myocardial ischemia
Esophageal
Doppler Useful in goal-directed therapy SV Esophageal probe Measures only descending aortic ﬂow
Assumptions about aortic size may be erroneous
The LiDCO plus monitor requires CO calibration with
lithium dilution once every eight hours according to the
manufacturer. It has been suggested, however, based on
recent data, that repeat calibration should take place during
major hemodynamic changes [37]. Cecconi et al. [38]c o n -
cluded that, for good precision, three lithium dilution mea-
surementsshouldbeperformed.Duringcalibration,isotonic
lithium chloride (150mM) is given intravenously (0.02 to
0.04mmol/kg). CO is derived from the dose and the area
under the concentration-time curve. Since lithium is only
distributed in the plasma fraction of blood, for the determi-
nation of CO, blood ﬂow is determined by dividing plasma
ﬂow by 1-packed cell volume, assessed on the basis of
hemoglobin/33 [2].
The accuracy of the Pulse CO algorithm may be compro-
mised under the following circumstances:
(i) aortic valve regurgitation,
(ii) post-aortic reconstruction,
(iii) intra-aortic balloon pump,6 Anesthesiology Research and Practice
(iv) highly damped peripheral arterial lines,
(v) severe peripheral arterial vasoconstriction,
(vi) inaccurate sodium and hemoglobin measurements,
(vii) arrhythmias,
(viii) intra- or extracardiac shunts.
In addition, each 1g/dL diﬀerence in hemoglobin artifactu-
ally results in a 4% change in the CO measurement [39].
Lithium therapy is a contraindication to the use of
LiDCO, as overestimation of CO occurs with elevated back-
ground levels. Some nondepolarizing muscle relaxants con-
tain high levels of quaternary ammonium residues, causing
the electrode to drift. Recalibration is recommended prior
to injection of the drugs or after the peak concentration has
fallen. Bolus dosing is also recommended if nondepolarizing
muscle relaxant use cannot be avoided.
The safety of lithium use has been well established. Since
lithium does not occur naturally in plasma, does not bind to
plasma or tissue proteins, and is not lost in passage through
the pulmonary circulation, tiny doses may be used. Levels
achievedare<1%oftherapeuticlevelsusedduringtreatment
of mania with lithium carbonate [36].
For the newer LiDCO rapid (Cambridge, UK), lithium
dilution has been replaced with a nomogram which has been
derived from in vivo data, to estimate CO. The system fea-
tures simplicity and ease of use. It was designed to provide
reliable hemodynamic trends, which would be useful for
goal-directed ﬂuid therapy. In a clinical setting where ab-
solute values for SV and SVR are required, a calibrated, sys-
tem is warranted [40].
7.1. Validation Studies. Investigators studying small patient
populations under diﬀerent clinical settings and with dif-
ferent reference standards have reported variable ﬁndings
regarding the accuracy of the LiDCO system. While some
have suggested acceptable accuracy [41–44], others have
found unacceptable accuracy compared to PAC-derived CO
[45, 46].
Linton et al. [35] studied 9 patients immediately after-
cardiac-surgery and reported good correlation (r = 0.89)
and a bias 0.3 (0.5) L/min between LiDCO and intermittent
bolus pulmonary artery TD (PATD). Costa et al. [47]r e p -
orted agreement between LiDCO and intermittent PATD in
23 after-liver-transplant patients exhibiting the typical hyp-
erdynamic circulation; the reported bias and 95% limit of
agreement for the PAC versus PulseCOLi were 0.29L/min
(r = 0.85) with a percentage error of 16.8%.
The validity of the device has also been studied in ped-
iatric patients. Kim et al. [48] reported good correlation
(r = 0.94) with PATD in 20 children (age range 2.5–15.5
years) undergoing cardiac catheterization. In smaller chil-
dren (<20kg), a separate analysis still showed good correla-
tion (0.89). Linton et al. [49] compared the device against
transpulmonary TD in 20 pediatric patients (age range 5
days–9 years) and also reported good accuracy (r = 0.96).
Yamashita et al. [46] compared bolus PATD with the
PulseCO, calibrated with CO by the TD method in patients
during cardiac-surgery. They found poor correlation (r =
0.49–0.55) and large bias (0.3–0.76), concluding that the
methods were not interchangeable. In an observational stu-
dy of 8 after-cardiac-surgery patients, McCoy et al. [45]
compared continuous cardiac index monitoring (CCI) with
LiDCO, using a peripheral iv line for indicator delivery.
The investigators found minimal bias (−0.01) but wide 95%
limits of agreement with respect to the mean, suggestive of
clinically signiﬁcant diﬀerences.
In a randomized controlled trial, Pearse et al. [50] used
LiDCO to guide goal-directed therapy (GDT) in high-risk
surgical patients. The outcome was fewer complications and
shorter length of hospital stay in the GDT group.
Costa et al. [51] carried out comparisons between the
LiDCO rapid and intermittent and continuous PATD in 10
after-liver-transplant patients. Their preliminary data show-
ed that, the LiDCO rapid provided acceptable readings, with
percentageerrorsof26and30%,respectively,comparedwith
intermittent and continuous PATD.
Multiple studies are ongoing using the LiDCO rapid to
gauge ﬂuid responsiveness and guide ﬂuid management.
[52–54]. The LiDCO rapid is also currently being used in a
largegovernment-supportedmulticentertrialcurrentlyund-
erway in the UK, OPTIMISE, aimed at improving surgical
outcomes by optimizing cardiovascular management [55].
8.Pulse ContourAnalysis
Pulse contour analysis for CO measurement is based on
the hypothesis that the area under the curve of the systolic
part of the arterial pressure waveform is proportional to the
SV [56]. Wesseling et al. [57] developed the ﬁrst successful
algorithms in the 1970’s, which continuously analyze the
pressure waveform from an arterial line. The area under
the systolic portion of the arterial pulse wave (measured
from the end of diastole to the end of the ejection phase)
dividedbytheaorticimpedancegivesameasureofthestroke
volume, which multiplied by the heart rate gives the cardiac
output.
8.1. The PiCCO System. The PiCCO system (PULSION Me-
dical Systems) is the ﬁrst pulse contour device to be intro-
duced into clinical practice [4, 56]. In 2007, the PiCCO2 re-
placed the PiCCO.
External manual calibration of the system is performed
via transpulmonary TD every eight hours, or up to hourly
during periods of hemodynamic instability [58, 59]. Blood
temperature changes from a thermo-indicator solution inj-
ected via a CVC are detected by a thermistor-tipped catheter,
typically placed in the femoral artery. Alternatively, the ra-
dial, axillary, or brachial artery may be used; however, longer
catheters are required to adequately assess the aortic pressure
wave signal from more distal sites. Although accuracy of
the transpulmonary TD technique may be aﬀected by the
longer transit time, errors due to airway pressure variation
are eliminated. The calibration is repeated three to ﬁve times
to obtain a calibration factor for calculation of continuous
CO, intrathoracic blood volume (ITBV), and extravascular
lung water (EVLW).Anesthesiology Research and Practice 7
Global end-diastolic volume (GEDV) is also measured
and, together with ITBV, is representative of cardiac preload
and EVLW. EVLW, comprising intracellular, interstitial, and
intra-alveolar water, is measured intermittently using trans-
pulmonary TD as a means of quantifying pulmonary edema
[60]. Systolic pressure variation and stroke volume variation
(SVV) provide information about volume status in mechan-
ically ventilated patients [32].
8.2. Limitations. The accuracy of analysis is inﬂuenced by
vascular compliance, aortic impedance, and peripheral arte-
rial resistance. Second generations of the system software ad-
dress issues related to diﬀerences in individual patients’ aor-
tic compliance and now analyze the shape of the waveform
and the pulsatile systolic area [61].
Results may be altered secondary to technical problems
such as air bubbles in the system, clotting of the catheter,
and inadequate indicator. Problems with analysis are also
seen with severe arrhythmias, raised EVLW (requiring more
indicator), aortic aneurysm (causes ITBV and GEDV to be
overestimated), severe valve insuﬃciency (CO is correct,
but preload is overestimated), and rapidly changing body
temperature. Recirculation of thermo-indicator may occur
in patients with intracardiac shunts and in pediatric patients
with open ductus Botalli [60].
8.3. Validation Studies. The pulse contour analysis method
has largely been found to correlate well against pulmonary
artery thermodilution (PATD) in numerous studies under
varying conditions, including coronary artery bypass graft-
ing (CABG) [62–65]. Some bias should be recognized, how-
ever, since TD is required for calibration [66]. Other inves-
tigators have reported large discrepancies between the two
techniques. Halvorsen et al. [67] reported unacceptably large
discrepancies with the PATD during oﬀ-pump CABG. For
lung transplantation, good correlation was found between
PiCCO and TD [68]. Signiﬁcant errors during periods of
hemodynamic instability, with the need for repeated recali-
bration has been reported [69]. In burn patients, good cor-
relation during low to normal CO was reported; however,
greater discrepancy was seen at high cardiac indices [70].
9.FloTrac/Vigileo
The FloTrac Vigileo (Edwards Lifesciences, LLC, Irvine Calif,
USA) is another pulse contour device, which was ﬁrst intro-
ducedinApril,2005[4].Thedevic epr o videsc ontin uousCO
measurement from a proprietary FloTrac sensor attached to
a standard peripheral arterial catheter, which is connected to
the Vigileo monitor. Calculations of SVR and SVV are also
displayed. A signiﬁcant feature of the system is that, unlike
PiCCO and Pulse CO, external calibration is not required
as the algorithm performs its own calibration using patient
demographicsandwaveformanalysis[4].Notably,nocentral
venous line is required.
The FloTrac algorithm integrates multiple characteristics
of the arterial pressure waveform with patient speciﬁc demo-
graphic data. Parameters include heart rate (HR), the sta-
ndarddeviationofthearterialpressure,ascalefactorpropor-
tional to vascular and peripheral resistance combined over
the arterial pressure waveform (mean, standard deviation,
skewness and kurtosis), pressure-dependent Windkessel, co-
mpliance and body surface area [71]. The standard deviation
of pulse pressures sampled over 20 seconds is correlated with
a predicted SV based on demographic data (age, gender,
height, and weight) and extrasystoles and other minor ar-
tifacts are eliminated via a beat-detection algorithm [37].
Impedance is also determined from the demographic data.
Vascular compliance and resistance are derived from arterial
waveform analysis [56].
Second generation versions (1.07 or later) undergo cali-
brationeveryminute,withimprovedCOmeasurementcom-
pared with earlier versions [37]. The third generation device,
with its Dynamic Tone Technology, is purported to use ad-
ditionalphysiologicvariables,withautomaticadjustmentfor
changes in vascular tone [72]. The third generation is under-
going investigations during hemodynamic instability, such
as sepsis and acute circulatory failure [73]. When used in
conjunctionwithacentralvenouspressurecatheter,systemic
vascular resistance (SVR) and systemic vascular resistance
index (SVRI) may be calculated [71].
9.1.Limitations. Sincethecalculationsdependontheﬁdelity
of the waveform, good arterial signal quality is critical to
accuracy of CO measurement. Unreliable measurements are
seen in the presence of arrhythmias and during intra-aortic
balloon pump use. Although any arterial site may be can-
nulated, Compton et al. [74] found errors introduced when
diﬀerent sites had mean arterial pressure (MAP) diﬀerences
of 5mmHg or more. Mayer et al. [75] reported the percent-
age error for the FloTrac/Vigileo in obese patients, with their
altered arterial compliance, to be slightly higher than that in
nonobese when compared with pulmonary artery TD.
9.2. Validation Studies. Although some investigators have
reported that the FloTrac appears to be reliable in several
situations, its reliability is questioned in hemodynamically
unstable patients [74, 76]. Manecke and Auger [77]f o u n d
satisfactory correlation with PATD for clinical use in after-
cardiac-surgery patients, and in a multicenter trial, McGee
et al. reported the FloTrac to be comparable to PATD in
critically ill patients [78].
Biancoﬁore et al. [79] found limited accuracy in patients
with low SVR who were undergoing liver surgery. Similarly,
Matthieu et al. [80]a n dK r e j c ie ta l .[ 81]f o u n dp o o ra g r e e -
ment in liver-transplant patients with low SVR compared
with PATD. Hamm et al. [71] compared the device with in-
stantaneous readings from a pulmonary artery catheter in
nine patients undergoing CABG and concluded that the two
were not clinically equivalent. Sakka et al. concluded that
transpulmonary TD was more accurate than with FloTrac in
septic patients [82].
The manufacturer reports that the system’s third gen-
eration algorithm (software version 3.02) has broadened
its database to include more patients with hyperdynamic
conditions and is undergoing investigation [72]. Mayer et al.
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percentage error of 46%) in patients undergoing CABG with
software version 1.03; however, they later reported percent-
age errors of 28.3% and 20.7% intraoperatively and ICU,
respectively, when studying the 1.1 software version in a
similar patient population [84].
Further studies are warranted to validate the device’s re-
liability under varying physiologic states. Hofer et al. [85]
compared the device with the PiCCO to determine how well
ﬂuidresponsivenesscouldbepredictedusingSVVandfound
similar accuracy. Suehiro and Okutani [86] concluded that
SVV as measured by the FloTrac system was able to predict
ﬂuid responsiveness in patients on one lung ventilation.
Highriskpatients undergoingmajorabdominal surgerywho
receivedgoal-directedﬂuidtherapyusingtheFloTrac/Vigileo
device (software version 1.14) were found to have fewer
complications and decreased hospital LOS [87].
10. The NICO System: Fick’s PrincipleUsing
Carbon Dioxide
The NICO system (Novametrix Medical Systems, Walling-
ford, Conn, USA), ﬁrst introduced in 1999 [4], uses the dif-
ferentialFickpartialrebreathingtechniquetomeasureCOin
intubated, sedated, mechanically ventilated patients.
Fick’s principle, using CO2 as an indicator, is rewritten as
follows:
CO =
VCO2
CvCO2 −CaCO2
,( 4 )
whereVCO2 iseliminationofCaCO2 andCvCO2 isarterialand
venous CO2 content, respectively.
CaCO2 may be calculated from the PaCO2 or estimated
fromtheend-tidalCO2.Diﬀusionabnormalitieslimittheac-
curacy of estimation [32]. VCO2 is calculated from the dif
ference between inspired and expired CO2 content. CvCO2 is
estimated by using a partial rebreathing technique.
A proprietary disposable rebreathing loop is attached to
the ventilator circuit, in addition to a mainstream infrared
CO2 sensor, a ﬁxed oriﬁce diﬀerential pressure pneumota-
chometer, and a rebreathing valve. Every three minutes, par-
tial rebreathing is initiated by opening the rebreathing valve,
which adds 150mL of dead space to the circuit. The dif-
ference between normal and rebreathing ratios are used to
calculate pulmonary blood ﬂow [4, 88]. Shunt correction is
carried out using Nunn’s isoshunt curves, a series of curves
thatdescribetherelationshipbetweenPaO2 andFiO2 fordif-
ferent levels of intrapulmonary shunt. Shunt is determined
by using the PaO2 and FiO2.
The intubated patients must be able to tolerate the brief
period of rebreathing. Ventilator settings may need adjust-
ment due to the at least 35mL of increased dead space int-
roduced.
10.1. Limitations. The normal diﬀerence between mixed ve-
nous and arterial CO2 tension is approximately 6mmHg.
Any increase, due, for example, to increased dead space,
would lead to changes in the calculated CO too. The PaCO2
andPvCO2 relationshipisonlyvalidwhenthePaCO2 ismore
than 30mmHg and when the CO2-Hgb dissociation curve is
linear. Hyperventilation to a PaCO2 < 30mmHg would lead
to inaccuracies in CO measurement. Since only nonshunted
blood is measured, the shunt fraction must be estimated for
an accurate measure of CO. The shunt fraction is estimated
using the shunt equation:
Qs
QT
=
CcO2 −CaO2
CcO2 −CvO2
(5)
where CaO2,C v O 2,a n dC a O 2 are the end-capillary, venous,
and arterial oxygen content. To measure these noninvasively,
Nunn’s isoshunt plots are used.
10.2.ValidationStudies. Variableresultshavebeenpublished
using this technique, with many studies involving patients
withvarieddegreesofintrapulmonaryshuntinsettingsfrom
cardiac-surgery or in hemodynamically unstable ICU pat-
ients [32]. Moderate agreement during thoracic surgery was
found compared with pulmonary artery TD [89].
Kotake et al. [90] found improved correlation with TD
withnewersoftwareversionscomparedwithpreviousstudies
in patients undergoing abdominal aortic aneurysm repair
[91]; however, they concluded that the technology still has
notreachedthelevelofinterchangeability. Ina smallstudy of
patients undergoing hip replacement, NICO was compared
to TD and a slight underestimation was found, with a small
degree of bias. For oﬀ-pump CABG patients, investigators
concluded that NICO reliably and more rapidly measured
CO compared with TD. The authors reported the tendency
tounderestimationperioperatively,butoverestimationinthe
postoperative period. The limits of agreement were reported
to be larger intraoperatively than postoperatively [92]. Sim-
ilar values were obtained from NICO and PATD for patients
beforeundergoing cardiopulmonary bypass (CPB);however,
after separation, NICO tended to underestimate CO [93].
Other investigators comparing NICO and TD for major
surgery or the ICU found that NICO slightly underestimated
CO compared to TD [94]. Following CABG, NICO had
insuﬃcient agreement with TD, as opposed to pulse contour
[95]. NICO was found to underestimate CO compared with
TD in ICU patients after cardiac-surgery and found least
suitable where CO was high [96]. Poor agreement was repo-
rted in a similar patient group [97]. Decreased correlation
has been reported in the setting of high CO, decreased
minute ventilation, increased intrapulmonary shunt, or sev-
ere chest trauma [32]. Rocco et al. [98]r e p o r t e db i a so f
−2.3L/min when Qs/Qp exceeded 35%.
11. Thoracic Bioimpedance
Thoracic bioimpedance (TEB) is the least invasive of the CO
monitors. The technology was ﬁrst developed by Kubicek et
al. [99] in the 1960’s, with the initial testing being carried
out on astronauts [100]. The basis for its use was later pio-
neeredbyLababidietal.[101]in1970,withsubsequentimp-
rovements carried out over the following decades, based on
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popularized based on studies by Shoemaker et al. in the
1990’s [100, 102].
Theunderlying theory isthatthe thoraxis acylinderper-
fused with ﬂuid (blood) which has a speciﬁc resistivity.
Bioimpedance is the electrical resistance to a high-frequency
low-amplitude current transmitted from electrodes placed
on the upper and lower thorax [32]. Typically, six electrodes
are placed—two on either side of the neck and four in the
lower thorax. Current transmitted from the outermost sur-
face electrodes is sensed by the innermost set of surface
electrodes.Theimpedance(Zo)iscalculatedfromthevoltage
changes, which are indirectly proportional to the volume of
ﬂuid in the thorax, such that increased ﬂuid results in low-
er TEB [103]. Blood ﬂow from the aorta is primarily res-
ponsible for the change in impedance. Stroke volume is est-
imated based on the formula
SV =
ρ

L2

Z2
Φ
 ·

VETx
(dz)
(dtmax)

,( 6 )
where ρ is the resistivity of blood (ohm-cm), L is the dis-
tance between electrodes (cm), ZΦ is the mean thoracic imp-
edance between electrodes (ohm), VET is the ventricular
ejection time (sec), and (dz/dt)max is the maximum negative
slope of the bioimpedance signal (ohm/sec) [89]. Several he-
modynamic parameters may be calculated using HR and
noninvasive blood pressure, together with the SV [103].
11.1. Limitations. TEB is aﬀected by a number of factors
[32]:
(i) changes in tissue ﬂuid volume,
(ii) respiration-induced changes in the volume of pul-
monary and venous (“noise” must be ﬁltered out
from the desired changes in volumetric blood ﬂow of
the aorta),
(iii) changes in electrode contact or position,
(iv) arrhythmias—the VET is determined using the inter-
v a lb e t w e e nQ R Sc o m p l e x e s ,
(v) acute changes in tissue water, for example, pulmo-
nary or chest wall edema or pleural eﬀusions,
(vi) noise from electrocautery, mechanical ventilation
and surgical manipulation,
(vii) changes in myocardial contractility, for example,
from anesthetic drugs or ischemia.
11.2. Validation Studies. Several investigators found that
TEB compared favorably with PATD in varying settings
including during cardiac catheterization, surgical patients,
and emergency room patients [102, 104–108]. Van De Water
et al. [109] found the TEB compared favorably with TD
in post cardiac surgical patients. K¨ o¨ obi et al. [110], using
whole-body impedance cardiography in CABG patients,
reported excellent repeatability which allowed for continu-
ous monitoring. Spiess et al. [111] used BioZ (SonoSite Inc,
Bothell, Wash,USA) intraoperatively for patients undergoing
CABG and found that the technique initially compared
well with TD, but, immediately postoperatively, the Bland-
Altman analysis was not as robust. Of note, good correlation
wasseenduringopeningofthechest.Spinaleetal.[112]used
TEB for post-CABG patients and found good correlation
with TD but poor correlation in patients who developed
severe tachycardia and frequent arrhythmias.
Severalinvestigatorshavefoundpoorreliabilityandpoor
correlation with PATD in after-cardiac-surgery, the critically
ill and the elderly [113–115]. In a meta-analysis performed
by Rotcajg et al. [116], the conclusion was that TEB might
be useful for trend analysis but not diagnostic interpretation.
Correlation appeared to be better with repeated measure-
ment designs. Atherosclerotic changes in the aorta of elderly
patients reduces the Windkessel eﬀect and contributes to
increased inaccuracy [114].
TEBappearsunlikelytobecomearoutinemonitorofCO
for anesthesia or critical care unless further reﬁnements in
signal processing occur.
12. Thoracic Bioreactance
Thoracic bioreactance technology developed as a reﬁnement
of TEB. Bioreactance analyses beat-to-beat changes in the
phase of electrical voltage signal relative to the applied
current signal across the thorax. Changes in intrathoracic
volumeproducevariationsinelectricalcapacitiveandinduc-
tive properties (bioreactance). The techniques for detecting
relative phase shifts are powerful and less aﬀected by
noise and external interference [115]. Thoracic bioreactance
technology is commercially available as the NICOM system
(Cheetah Medical Inc., Indianapolis, Ind, USA). Two dual-
electrode stickers are placed on either side of the thorax—
one electrode is used to inject the sine-wave high-frequency
(75kHz) current into the body and the other is used by
the voltage input ampliﬁer [115]. The ﬁnal measurement is
determined by averaging the 2 signals.
12.1. Validation Studies. Several validation studies of tho-
racic bioreactance have been conducted, using continuous
PATD as the reference continuous technique. Investigators
report good correlation between the two methods (r =
0.64–0.9) and minimal bias [115–117]. Comparisons are
limited by diﬀerences in intrinsic variability of measure-
ments of PATD and diﬀerences in the time responsiveness
of the 2 modalities. In addition, PATD only measures right
ventricular output, excluding the bronchial circulation. For
this reason, Rotcajg et al. [116] considered 20% bias and
precision as acceptable.
Smaller studies comparing NICOM with PICCO and
Vigileodevicesreportsimilarcapabilitiesbetweenthedevices
[116, 118].
12.2. Limitations. The assumption that the area under the
ﬂow pulse is proportional to the product of peak ﬂow and
VET may not be valid under periods of low ﬂow, and
readings may have decreased accuracy [115].
13. Endotracheal CardiacOutputMonitor
The endotracheal cardiac output monitor (ECOM; Con-
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plethysmography.Theascendingaortaliesincloseproximity
to the trachea. Using the principle of bioimpedance, a low
frequency current of 2mA and 200 kHz is delivered from
electrodes attached to a standard endotracheal tube (ETT)
[119].
The ECOM 6 3D endotracheal tube (ETT) is a standard
ETT to which are attached three orthogonal pairs of sensing
electrodes on the cuﬀ. Current is delivered between an elec-
trode on the shaft of ETT and the number three electrode
on the balloon. The sensing electrodes on the cuﬀ detect
the change in impedance secondary to aortic blood ﬂow.
The three-dimensional array allows for up to twelve combi-
nations of electrodes which may be used for measurement
of ﬂow. This compensates for positional and anatomical
diﬀerences between the cuﬀ and aorta [119].
A proprietary algorithm calculates SV based on impeda-
nce changes. Increased blood ﬂow in the aorta leads to de-
creased impedance. Apart from CO, also displayed are HR,
ECG waveforms, SV, CI, and SVR [120].
13.1. Limitations. Coronary blood ﬂow, which represents
about 4-5% of CO is not recorded. Electrocautery produces
interference.
13.2. Validation Studies. The technology is not yet fully vali-
datedinhumans.Aporcinestudyfoundexcellentcorrelation
when compared with transit time ﬂow probes [120]. A study
in cardiac-surgery patients reported poor correlation with
TD, wide limits of agreement and a large percentage error
[121].
14.UltrasoundDilution
Ultrasound dilution (UD) is a minimally invasive technique,
ﬁrstintroducedin1995,andwidelyusedinhemodialysisand
in extracorporeal membrane oxygenation (ECMO) to mea-
sure shunt ﬂow, vascular access recirculation and CO [122].
The technique uses isotonic saline as an indicator to measure
hemodynamic variables.
The underlying principle is that blood ultrasound veloc-
ityisafunctionoftotalbloodproteinconcentration,temper-
ature and plasma average ion concentration. The injection of
isotonicsalineresultsindecreasedbloodultrasoundvelocity,
from which dilution curves can be produced [123]. The
setup involves a disposable tubing, which is used to create an
extracorporeal loop between existing peripheral arterial and
c e n t r a lv e n o u sc a t h e t e r s .T h ea r t e r i o v e n o u sl o o pi sp r i m e d
with heparinized saline. A roller pump circulates blood from
the artery to the vein. Two reusable sensors are clamped onto
the arterial venous limbs of the loop. These sensors measure
the changes in blood ultrasound velocity and blood ﬂow
following a bolus of saline injected into the venous side. The
CO calculation is based on the Stewart-Hamilton principle
[123].
14.1. Validation Studies. Relatively few studies investigating
the technology have been undertaken thus far. Galstyan et
al. [122] compared CO and blood volumes using UD and
PiCCO technology in adult ICU patients and concluded that
the two were equivalent and interchangeable in that patient
population. PiCCO blood volumes were signiﬁcantly higher.
The technology appears to be able to be used in diﬀerent
patient population groups. Krivitski et al. [123]p e r f o r m e d
in vitro studies to conﬁrm the ability of UD technology to
measure small ﬂows and volumes in pediatric patients and
neonates.Tsutsuietal.[124]foundgoodcorrelationwithTD
in patients undergoing abdominal surgery.
15.Transesophageal Echocardiography
Transesophageal echocardiography (TEE) is widely used in
the perioperative setting for evaluating cardiac anatomy and
function.DopplertechniquesforthemeasurementofCOare
most commonly based on Simpson’s rule. Early operators
made determinations using the pulmonary artery, which
onlyreﬂectsrightventricularCO.Two-dimensionalechocar-
diography determined the cross-sectional area of the PA,
which was multiplied by the integral of the instantaneous
ﬂow velocity, determined by pulsed wave Doppler in the
plane of the cross section [125] .Ad r a w b a c ki sd i ﬃculty vis-
ualizing the PA in a signiﬁcant number of patients because it
may be obscured by the left main stem bronchus.
The validated frequently used technique developed by
Perrino et al. [126] determines the cross-sectional area of the
left ventricular outﬂow tract (CSALVOT) in a mid-esophageal
aortic long axis view. Planimetry is used to measure the
area of the aortic valve. To measure aortic blood ﬂow, the
probe is positioned in a transgastric short-axis view of the
left ventricle at the mid-papillary level. The image array is
rotated approximately 120◦ to produce imaging of the LVOT
and ascending aorta lying parallel to the ultrasound beam.
Continuous-wave Doppler is used to measure aortic blood
ﬂow velocities at the level of the aortic valve. Doppler CO
is calculated as a product of the velocity time integral,
CSALVOT, and HR [127]. Another method described uses
the transgastric, apical view to assess aortic blood ﬂow. The
ultrasound beam is oriented almost parallel to the aortic
valve blood ﬂow. Probe positioning for this view is techni-
cally challenging [61].
16. Esophageal Doppler
Esophageal Doppler (ED) utilizes a ﬂexible probe, approxi-
mately the size of a nasogastric tube, at the tip of which is a
transducer (4MHz continuous or 5MHz pulsed wave). The
probe may be left in place for days to weeks in intubated,
sedated, mechanically ventilated patients. When advanced
to the mid-thoracic level, ideally between the 5th and 6th
thoracic vertebrae, the device is parallel to and thus able to
measure blood ﬂow velocity in the descending aorta [128]. It
is assumed that the aorta is a cylinder and ﬂow is calculated
by multiplying the cross-sectional area (CSa) by the velocity
(Vf). Since velocity changes with pulsatility of ﬂow, Vf is
describedastheareaunderthecurveofavelocity-timegraph
[32]. The area is calculated as the integral of the velocity
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blood ﬂow (T0 and T1, resp.). This area, known as the stroke
distance, is the distance travelled by the blood during systole
(cm). This value is multiplied by the CSAa. The aortic area
may be derived either from published nomograms or direct
measurement [32]:
CO = HR ×SV. (7)
SV changes can be used to guide ﬂuid administration. ED
alsohasthecapabilityofdeterminingthecorrectedtimeﬂow
(FTc), which is the systolic ﬂow time corrected for an HR
of 60/min. This value, which represents the time from the
beginning of the aortic waveform upstroke to its return to
baseline, is used as a measure of cardiac preload. Good
correlation with other techniques, such as pulmonary artery
occlusion pressure, along with improved outcomes has been
reported [129–132].
16.1. Limitations. Only descending aortic blood ﬂow, which
represents about 70% of total ﬂow, is measured, and so a
correction factor (K-factor) must be added to compensate
for the blood ﬂow to aortic arch vessels. This ﬂow ratio may
vary with metabolic activity, between diﬀerent organs and
duringhemodynamicinstability,andthevalidityisquestion-
able outside of young healthy patients [32]. An inconstant
proportion of blood ﬂow to the descending aorta may also
occur in the setting of aortic coarctation, aortic cross clamp,
andpregnancy.Turbulenceduetothoracicaneurysms,aortic
balloon pump, aortic valve disease interfere with the validity
of results [133].
CSAa changes with variations in pulse pressure, vascular
tone, aortic compliance, volume status, or catecholamine
use. Direct measurement produces greater accuracy [32]. In
76 patients with acute circulatory failure, measurements of
aortic blood ﬂow before and after a ﬂuid bolus revealed
an underestimation of the response to the ﬂuid bolus in a
signiﬁcant number of patients if readings were based on an
estimated unchanged CSAa as opposed to directly measured
aortic velocity and CSAa [134]. Proper probe position is
essential to accuracy of determination of Vf. The Doppler
beam must be within 20◦ of axial ﬂow to obtain good mea-
surement.
With respect to ﬂuid management, interpretation of FTc
may be complicated by its inverse relationship with SVR. In
conditions of elevated SVR, such as heart failure or exces-
sive vasopressor use, FTc is reduced and may prompt ﬂu-
idadministration.Otherconditions,suchaspericardialtam-
ponade or mitral stenosis, where there is limited cardiac ﬁll-
ing will produce a decreased FTc and again prompt further
ﬂuid administration in a scenario where the patient may al-
readyhaveoptimal cardiacﬁllingbasedonthestarlingcurve.
S Vh a st h u sb e e na r g u e dt ob eap r e f e r a b l ev a r i a b l et om o n -
itor ﬂuid status [135, 136].
16.2. Validation Studies. Multiple studies have compared the
validity of ED for measurement of CO against PATD under
varying conditions [129, 137–139]. Dark and Singer [139]
published a meta-analysis of eleven studies in critically
ill patients, ﬁnding a pooled median bias of 0.19L/min
(range: −0.69–2.0L/min) for CO. Boulnois and Pechoux
[140] reported the pooled limits of agreement for 3 studies
including 90 patients under a range of ﬂow states to be −2.21
to 2.33L/min. Laupland and Bands [133], in a meta-analysis
of 25 studies, concluded that ED was reliable, responsive to
changes, was showed good agreement with low bias, how-
ever, the wide limits of agreement raised concerns about pre-
cision. The two techniques are therefore not thought to be
interchangeable; however, ED may be used to track changes
[137].
Improved patient outcome has been demonstrated by a
number of investigators when ED is used in goal-directed
ﬂuid therapy. Sinclair et al. [132] reported ED-guided ﬂuid
loading resulted in greater improvements in SV and CO with
ﬂuid administration in study patients, as well as faster reco-
very and decreased LOS than in controls. Venn et al. [141]
similarly reported reduced hypotension and faster recovery
for ED-monitored patients undergoing femoral fracture re-
pair, compared with controls who received central venous
pressure monitoring. In patients having major elective sur-
gery, Gan et al. [142] reported earlier return to bowel fun-
ction and decreased incidence of postoperative nausea and
vomiting. Mythen and Webb [131] found a decreased in-
cidence of gut mucosal perfusion (measured by gastric to-
nometry), major complications, and decreased hospital and
ICU stay in cardiac-surgery patients who received goal-
directed colloid therapy guided by ED compared with stand-
ard management. Wakeling et al. [143] randomized 128 pa-
tients receiving colorectal surgery to ﬂuid management with
guided with ED or central venous pressure monitoring. De-
creased hospital LOS and faster gut recovery were seen in
the ED-guided group. Noblett et al. [144] reported shorter
hospitalstayanddecreasedmorbidityinpatientsundergoing
colorectal resection who received ED-guided ﬂuid manage-
ment. Additionally, the intervention group had lower levels
ofinterleukin6,whichmaybeareﬂectionofimprovedbowel
perfusion. Conway et al. [145]r e p o r t e di m p r o v e dh e m o -
dynamics in patients having major bowel surgery and fewer
ICU admissions. In trauma patients, ED-guided ﬂuid ther-
apy resulted in decreased blood lactate levels, reduced infect-
ious complications and decreased hospital and ICU LOS
[146].AnursedeliveredED-guidedﬂuidprotocolinpatients
after-cardiac-surgery resulted in shortened hospital LOS
[147].
17. Conclusion
Despite controversies, complications, and inherent errors in
measurement, intermittent bolus PATD CO measurement
continues to be the gold standard. Newer techniques provide
less invasive alternatives and will be increasingly adopted
over time; however, the currently available monitors are still
unable to provide central circulation pressures or true mixed
venous saturations and cannot replace the PAC [32]. Many
minimally invasive techniques continue to suﬀer from de-
creased accuracy and reliability under periods of hemody-
namic instability, and so few have reached the level of inter-
changeability with the PAC. Esophageal Doppler and pulse12 Anesthesiology Research and Practice
contour monitors have the advantage of being able to predict
ﬂuid responsiveness. Their use in GDT has already been
shown to decrease postoperative morbidity, and the use of
thesetechnologiesisanticipatedtocontinuetoleadtogreater
improvement in outcomes [32].
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